Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22989079 | 0.93 | — | — | |
| SCHEMBL22989015 | 0.89 | — | — | |
| SCHEMBL22989010 | 0.89 | PRKDC (0.34) | PRKDC | |
| SCHEMBL22989040 | 0.89 | PRKDC (0.36) | PRKDC | |
| SCHEMBL22989007 | 0.88 | — | — | |
| SCHEMBL22989013 | 0.88 | MEN1 (0.31) | PRKDC | |
| SCHEMBL22989011 | 0.87 | TSHR (0.31) | — | |
| SCHEMBL22989214 | 0.86 | — | — | |
| SCHEMBL22989075 | 0.86 | PRKDC (0.35) | PRKDC | |
| SCHEMBL22989139 | 0.86 | PRKDC (0.33) | PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021029757-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | 주식회사 엘지화학 | 2021-02-18 | — | — | WO | disclosed |
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | PRKDC 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.